Literature DB >> 16973378

Expression, purification, and characterization of stable, recombinant human adenylosuccinate lyase.

Peychii Lee1, Roberta F Colman.   

Abstract

The full length human adenylosuccinate lyase gene was generated by a PCR method using a plasmid encoding a truncated human enzyme as template, and was cloned into a pET-14b vector. Human adenylosuccinate lyase was overexpressed in Escherichia coli Rosetta 2(DE3)pLysS as an N-terminal histidine-tagged protein and was purified to homogeneity by a nickel-nitriloacetic acid column at room temperature. The histidine tag was removed from the human enzyme by thrombin digestion and the adenylosuccinate lyase was purified by Sephadex G-100 gel filtration. The histidine-tagged and non-tagged adenylosuccinate lyases exhibit similar values of Vmax and Km for S-AMP. Analytical ultracentrifugation and circular dichroism revealed, respectively, that the histidine-tagged enzyme is in tetrameric form with a molecular weight of 220 kDa and contains predominantly alpha-helical structure. This is the first purification procedure to yield a stable form of human adenylosuccinate lyase. The enzyme is stable for at least 5 days at 25 degrees C, and upon rapid freezing and thawing. Temperature as well as reducing agent (DTT) play critical roles in determining the stability of the human adenylosuccinate lyase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973378     DOI: 10.1016/j.pep.2006.07.023

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  9 in total

1.  Yeast Cell Wall Chitin Reduces Wine Haze Formation.

Authors:  Thulile Ndlovu; Benoit Divol; Florian F Bauer
Journal:  Appl Environ Microbiol       Date:  2018-06-18       Impact factor: 4.792

2.  Structural and biochemical characterization of human adenylosuccinate lyase (ADSL) and the R303C ADSL deficiency-associated mutation.

Authors:  Stephen P Ray; Michelle K Deaton; Glenn C Capodagli; Lauren A F Calkins; Lucas Sawle; Kingshuk Ghosh; David Patterson; Scott D Pegan
Journal:  Biochemistry       Date:  2012-08-07       Impact factor: 3.162

3.  In vitro hybridization and separation of hybrids of human adenylosuccinate lyase from wild-type and disease-associated mutant enzymes.

Authors:  Lushanti De Zoysa Ariyananda; Christina Antonopoulos; Jenna Currier; Roberta F Colman
Journal:  Biochemistry       Date:  2011-02-03       Impact factor: 3.162

4.  Important roles of hydroxylic amino acid residues in the function of Bacillus subtilis adenylosuccinate lyase.

Authors:  Mark L Segall; Meghan A Cashman; Roberta F Colman
Journal:  Protein Sci       Date:  2007-03       Impact factor: 6.725

5.  Biochemical and biophysical analysis of five disease-associated human adenylosuccinate lyase mutants.

Authors:  Lushanti De Zoysa Ariyananda; Peychii Lee; Christina Antonopoulos; Roberta F Colman
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

6.  Effect of a new non-cleavable substrate analog on wild-type and serine mutants in the signature sequence of adenylosuccinate lyase of Bacillus subtilis and Homo sapiens.

Authors:  Sharmila Sivendran; Roberta F Colman
Journal:  Protein Sci       Date:  2008-05-09       Impact factor: 6.725

7.  SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions.

Authors:  Kirstie E Keller; Irene S Tan; Young-Sam Lee
Journal:  Science       Date:  2012-10-18       Impact factor: 47.728

8.  Colocalization and Sequential Enzyme Activity in Aqueous Biphasic Systems: Experiments and Modeling.

Authors:  Bradley W Davis; William M Aumiller; Negar Hashemian; Songon An; Antonios Armaou; Christine D Keating
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

9.  Molecular comparison of Neanderthal and Modern Human adenylosuccinate lyase.

Authors:  Bart Van Laer; Ulrike Kapp; Montserrat Soler-Lopez; Kaja Moczulska; Svante Pääbo; Gordon Leonard; Christoph Mueller-Dieckmann
Journal:  Sci Rep       Date:  2018-12-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.